Ensuring Its Value: Validated Cost Effectiveness of Medtronic Reveal LINQ
The UK’s National Institute for Health and Care Excellence (NICE) has assessed the clinical and economic effectiveness of Implantable Cardiac Monitors (ICMs) in cryptogenic stroke patients and has published a Diagnostic Guidance on Implantable Cardiac Monitors on August 7, 2020. A rigorous clinical and economic analysis shows Reveal LINQ Insertable Cardiac Monitor as the only ICM to have sufficient evidence to be recommended for patients following a cryptogenic stroke after external monitoring has been done and a cardiac arrhythmic cause of stroke is suspected. This live webinar will discuss implications for international healthcare systems and healthcare providers based on the NICE recommendations.
Key opinion leaders in the field of stroke care will share their perspective on the new Diagnostic Guidance and explain how these recommendations should guide use of ICMs in the treatment of stroke patients.
Please join us to learn more about Reveal LINQ ICM and its benefit for reducing secondary stroke.
This webinar is supported by:
- What is the NICE Diagnostic Assessment Programme (DAP)
- What evidence leads to the conclusion that LINQ is cost-effective in cryptogenic stroke patients after external ECG monitoring?
- How does NICE decide if a medical technology is cost-effective? The concept of Quality Adjust Life Years (QALY) and the applied cost-effectiveness threshold
- The different clinical scenarios modelled: Remote Monitoring with FocusOn is a cost-effective tool for increasing capacity to monitor patients
- What the NICE Diagnostic Guidance means for your practice and how it could translate to greater efficiency in care
- General Clinical Cardiology
- Interventional Cardiology
- Neurology (General and Vascular Neurology)
- Stroke unit physicians and nurses
- Cardiology and Neurology Nurses
- Hospital Administrators
- Hospital Buyers
- Healthcare system administrators
- Health ministry officials